Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia

Publication date: August 2017
Source:Hematology/Oncology Clinics of North America, Volume 31, Issue 4
Author(s): Jerald P. Radich, Michael J. Mauro

Teaser

Chronic myeloid leukemia (CML) is a myeloproliferative disorder that accounts for approximately 10% of new cases of leukemia. The introduction of tyrosine kinase inhibitors has led to a reduction in mortalities. Thus, the estimated prevalence of CML is increasing. The National Comprehensive Cancer Network and the European Leukemia Net guidelines incorporate frequent molecular monitoring of the fusion BCR-ABL transcript to ensure that patients reach and keep treatment milestones. Most patients with CML are diagnosed in the chronic phase, and approximately 10% to 30% of these patients will at some time in their course meet definition criteria of resistance to imatinib.


http://ift.tt/2tD8hkI